Acquired by Allergan Inc in 2015, Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs), which modulate the receptor in a different way than existing NMDAR agents. The company's drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurex's platform of novel NMDAR modulators. As of August 2015, Naurex, Inc. has operated as a subsidiary of Allergan plc. Coincident with the aquisition, Naurex Inc. spun off its discovery platform for N-methyl-D-aspartic acid (NMDA) modulators to include the new company owning Naurex's medical chemistry and related IP.